Estonia - estonio - Ravimiamet

sandoz pharmaceuticals d.d. - tenofoviirdisoproksiil - õhukese polümeerikattega tablett - 245mg 60tk; 245mg 30tk

Estonia - estonio - Ravimiamet

first pharma oÜ - ramipriil+hüdroklorotiasiid - tablett - 5mg+25mg 28tk; 5mg+25mg 50tk; 5mg+25mg 14tk; 5mg+25mg 300tk; 5mg+25mg 45tk; 5mg+25mg 10tk; 5mg+25mg 20tk

Unión Europea - estonio - EMA (European Medicines Agency)

eli lilly nederland b.v. - drotrekogiin alfa (aktiveeritud) - sepsis; multiple organ failure - antitrombootilised ained - xigris on näidustatud täiskasvanud raskete sepsisega patsientide raviks, kellel esineb mitu organi puudulikkust, kui nad lisatakse parimale standardsele ravile. xigris'i kasutamist tuleb arvestada peamiselt olukordades, kus ravi saab alustada 24 tunni jooksul pärast organi kahjustuse tekkimist (lisateavet vt lõik 5.

Estonia - estonio - Ravimiamet

novartis baltics sia - deksametasoon+neomütsiin+polümüksiin b - silmatilgad, suspensioon - 1mg+3500rÜ+6000rÜ 1ml 5ml 1tk

Estonia - estonio - Ravimiamet

sandoz pharmaceuticals d.d. - vankomütsiin - infusioonilahuse pulber - 1000mg 10tk; 1000mg 5tk

Estonia - estonio - Ravimiamet

novartis baltics sia - deksametasoon+tobramütsiin - silmasalv - 1mg+3mg 1g 3.5g 1tk

Estonia - estonio - Ravimiamet

novartis baltics sia - tobramütsiin - silmatilgad, lahus - 3mg 1ml 5ml 1tk

Estonia - estonio - Ravimiamet

novartis baltics sia - tobramütsiin - silmasalv - 3mg 1g 3.5g 1tk

Unión Europea - estonio - EMA (European Medicines Agency)

laboratoire hra pharma - ulipristaal - kontraceptsioon, postkoital - suguhormoonid ja genitaalsüsteemi, , hädaabi rasestumisvastased vahendid - hädaabi kontratseptsioon 120 tundi (5 päeva) rasestumisvastaseid vahendeid või kaitsmata seksuaalvahekorras.

Unión Europea - estonio - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - kartsinoom, mitteväikerakk-kopsu - muud antineoplastilised ained, protein kinase inhibiitorid - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.